In the Boardroom
Refine search
Pharmaceutical
Important research news last week included Vertex announcing positive Phase III results for its povetacicept in immunoglobulin A nephropathy. And, BridgeBio reported positive Phase III results for BBP-418 in muscular dystrophy. Also of note, German biotech BioNTech revealed that its co-founders were planning to leave the company, along with 2025 financial results. 15 March 2026
Pharmaceutical
Ratio Therapeutics, a US pharma company developing radiopharmaceuticals for cancer treatment and monitoring, has announced the appointment of Colin Hayward as chief medical officer (CMO). 13 March 2026
Pharmaceutical
Swiss neurotechnology firm MindMaze Therapeutics has appointed healthtech executive Zach Henderson as chief executive, as the company looks to expand adoption of its FDA-cleared neurorestorative platform in the USA. 12 March 2026
Pharmaceutical
French drugmaker Ipsen has announced the appointment of Michelle Werner as executive vice president, president of North America, effective March 23. 12 March 2026
Pharmaceutical
Danish neuroscience specialist Lundbeck has appointed Markus Kede as senior vice president and chief AI officer, creating a new executive role to accelerate the company’s use of artificial intelligence across research and commercial operations. 10 March 2026
Pharmaceutical
Swiss specialty drugmaker Santhera Pharmaceuticals has appointed Marc Clausse as chief commercial officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will retire after 11 years with Santhera and will remain available to support an orderly transition over the coming months. 10 March 2026
Pharmaceutical
Seattle-based Nautilus Biotechnology, a specialist in single-molecule proteome analysis, has announced the appointment of Amber Faust as vice president of sales. 6 March 2026
Pharmaceutical
Swedish specialty pharma Orexo is reorganizing its management team as it pivots away from direct US commercialization following the divestment of opioid dependence treatment Zubsolv (buprenorphine/naloxone). 6 March 2026
Pharmaceutical
USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as chief executive. 5 March 2026
Pharmaceutical
US neuro-focused company NeuroOne has appointed David Wambeke as chief business officer, tasking him with leading the firm’s drug delivery program as it seeks partnerships around its neurological treatment platform. 4 March 2026
Pharmaceutical
US clinical-stage biotech Latigo Biotherapeutics has appointed Neha Krishnamohan as chief financial officer and chief business officer, adding a finance executive with experience across biotech capital markets and corporate strategy as the company advances its non-opioid pain pipeline. 4 March 2026
Pharmaceutical
Scotland-based contract development and manufacturing organization (CDMO) Symbiosis Pharmaceutical Services, a specialist in the GMP sterile fill-finish manufacturing of injectable drug products, has announced the appointment of Joanne Anderson as its chief commercial officer (CCO). 3 March 2026
Pharmaceutical
Ireland headquartered Alkermes (Nasdaq: ALKS) has announced that Richard Pops will retire from his role as chief executive (CEO), effective July 31, 2026. 26 February 2026
Pharmaceutical
UK biotech N4 Pharma has appointed David Solomon as chief executive and unveiled plans to rename itself Thalia Therapeutics, marking a decisive shift into proprietary RNA medicines focused initially on cardiovascular disease. 24 February 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello has announced that Henriette Mersebach will step down imminently as executive vice president, research and development, and as a member of the board. 20 February 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo has appointed Dr John Tsai as its new global head of R&D, to succeed Dr Ken Takeshita, who is stepping down from his post effective April 1, 2026. 20 February 2026
Pharmaceutical
US dermatology specialist Verrica Pharmaceuticals has announced the appointment of Chris Chapman as its chief commercial officer (CCO). 13 February 2026
Pharmaceutical
French pharma major Sanofi's board of directors has decided not to renew the director mandate of Paul Hudson. As a result, Paul Hudson’s last day as chief executive (CEO) will be on February 17, 2026 at the end of business. 12 February 2026
Pharmaceutical
German CDMO Rentschler Biopharma has appointed Veit Bergendahl as chief operating officer and a member of its executive board, effective from April. 11 February 2026
Pharmaceutical
Canada headquartered Helus Pharma, a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (NSAs), today announced the appointment of Michael Cola as chief executive (CEO), effective immediately. 11 February 2026
Pharmaceutical
Important research news last week included Vertex announcing positive Phase III results for its povetacicept in immunoglobulin A nephropathy. And, BridgeBio reported positive Phase III results for BBP-418 in muscular dystrophy. Also of note, German biotech BioNTech revealed that its co-founders were planning to leave the company, along with 2025 financial results. 15 March 2026
Pharmaceutical
Ratio Therapeutics, a US pharma company developing radiopharmaceuticals for cancer treatment and monitoring, has announced the appointment of Colin Hayward as chief medical officer (CMO). 13 March 2026
Pharmaceutical
Swiss neurotechnology firm MindMaze Therapeutics has appointed healthtech executive Zach Henderson as chief executive, as the company looks to expand adoption of its FDA-cleared neurorestorative platform in the USA. 12 March 2026
Pharmaceutical
French drugmaker Ipsen has announced the appointment of Michelle Werner as executive vice president, president of North America, effective March 23. 12 March 2026
Pharmaceutical
Danish neuroscience specialist Lundbeck has appointed Markus Kede as senior vice president and chief AI officer, creating a new executive role to accelerate the company’s use of artificial intelligence across research and commercial operations. 10 March 2026
Pharmaceutical
Swiss specialty drugmaker Santhera Pharmaceuticals has appointed Marc Clausse as chief commercial officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will retire after 11 years with Santhera and will remain available to support an orderly transition over the coming months. 10 March 2026
Pharmaceutical
Seattle-based Nautilus Biotechnology, a specialist in single-molecule proteome analysis, has announced the appointment of Amber Faust as vice president of sales. 6 March 2026
Pharmaceutical
Swedish specialty pharma Orexo is reorganizing its management team as it pivots away from direct US commercialization following the divestment of opioid dependence treatment Zubsolv (buprenorphine/naloxone). 6 March 2026
Pharmaceutical
USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as chief executive. 5 March 2026
Pharmaceutical
US neuro-focused company NeuroOne has appointed David Wambeke as chief business officer, tasking him with leading the firm’s drug delivery program as it seeks partnerships around its neurological treatment platform. 4 March 2026
Pharmaceutical
US clinical-stage biotech Latigo Biotherapeutics has appointed Neha Krishnamohan as chief financial officer and chief business officer, adding a finance executive with experience across biotech capital markets and corporate strategy as the company advances its non-opioid pain pipeline. 4 March 2026
Pharmaceutical
Scotland-based contract development and manufacturing organization (CDMO) Symbiosis Pharmaceutical Services, a specialist in the GMP sterile fill-finish manufacturing of injectable drug products, has announced the appointment of Joanne Anderson as its chief commercial officer (CCO). 3 March 2026
Pharmaceutical
Ireland headquartered Alkermes (Nasdaq: ALKS) has announced that Richard Pops will retire from his role as chief executive (CEO), effective July 31, 2026. 26 February 2026
Pharmaceutical
UK biotech N4 Pharma has appointed David Solomon as chief executive and unveiled plans to rename itself Thalia Therapeutics, marking a decisive shift into proprietary RNA medicines focused initially on cardiovascular disease. 24 February 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello has announced that Henriette Mersebach will step down imminently as executive vice president, research and development, and as a member of the board. 20 February 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo has appointed Dr John Tsai as its new global head of R&D, to succeed Dr Ken Takeshita, who is stepping down from his post effective April 1, 2026. 20 February 2026
Pharmaceutical
US dermatology specialist Verrica Pharmaceuticals has announced the appointment of Chris Chapman as its chief commercial officer (CCO). 13 February 2026
Pharmaceutical
French pharma major Sanofi's board of directors has decided not to renew the director mandate of Paul Hudson. As a result, Paul Hudson’s last day as chief executive (CEO) will be on February 17, 2026 at the end of business. 12 February 2026
Pharmaceutical
German CDMO Rentschler Biopharma has appointed Veit Bergendahl as chief operating officer and a member of its executive board, effective from April. 11 February 2026
Pharmaceutical
Canada headquartered Helus Pharma, a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (NSAs), today announced the appointment of Michael Cola as chief executive (CEO), effective immediately. 11 February 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze